BridgeBio Pharma Operating Expenses 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
Dr Reddy's Laboratories (RDY)	$11.9B
Bausch Health Cos (BHC)	$2.9B
Amphastar Pharmaceuticals (AMPH)	$2.2B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$506M
Personalis (PSNL)	$245M
Assembly Biosciences (ASMB)	$96M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M